How should new or worsening tendon pain be managed in a patient taking tramadol?

Tramadol Does Not Cause Tendon Pain and Should Not Be Discontinued for This Reason

There is no established causal relationship between tramadol use and tendon pain or tendinopathy. If a patient on tramadol develops new or worsening tendon pain, the focus should be on diagnosing and treating the underlying tendon pathology itself, not on discontinuing tramadol.

Understanding the Clinical Context

Tramadol is a weak μ-opioid receptor agonist with dual mechanism of action through serotonin and norepinephrine reuptake inhibition 1. It is widely used for moderate to moderately severe pain across multiple conditions including neuropathic pain, osteoarthritis, and musculoskeletal injuries 1, 2, 3.

The evidence does not support tramadol as a cause of tendon pathology. In fact, one small study demonstrated tramadol's use as a local anesthetic during tendon repair surgery of the hand, showing it provided effective local anesthesia without adverse effects on tendon tissue 4. This suggests tramadol does not have inherent tendon toxicity.

Management Algorithm for Tendon Pain in Patients Taking Tramadol

Step 1: Evaluate the Tendon Pathology

• Assess for overuse tendinopathy (rotator cuff, patellar, Achilles, lateral/medial epicondyle)
• Consider imaging: ultrasound for tendon thickening and tears; MRI for detailed assessment of degenerative changes 5
• Determine if this is acute inflammatory tendonitis versus chronic degenerative tendinopathy 5

Step 2: Treat the Tendon Condition Appropriately

For acute/subacute tendon pain:

• Topical NSAIDs with or without menthol gel as first-line 6
• Relative rest (avoid complete immobilization; continue activities that don't worsen pain) 5
• Cryotherapy: ice through wet towel for 10-minute periods 5
• Eccentric exercise programs once acute phase resolves 5

For chronic tendinopathy:

• NSAIDs have limited benefit since most chronic tendinopathies lack significant inflammation 5
• Focus on physical therapy with eccentric strengthening 5
• Consider corticosteroid injections peritendinously (NOT intratendinous) for acute flares, though long-term benefit is unclear 5

Step 3: Continue or Adjust Tramadol Based on Pain Management Needs

Continue tramadol if:

• It is providing effective analgesia for the patient's primary pain condition
• The patient tolerates it well without significant adverse effects
• The tendon pain represents a new, separate pathology requiring its own treatment

Consider tramadol for the tendon pain itself if:

• First-line treatments (topical NSAIDs, physical therapy) are insufficient 6
• The patient has contraindications to oral NSAIDs 2, 3
• Moderate to severe pain persists despite conservative measures

However, recent evidence suggests caution with tramadol for musculoskeletal injuries. A 2020 guideline conditionally recommends against tramadol for acute non-low back musculoskeletal injuries due to limited benefit and risk of adverse effects 6. A 2025 systematic review found tramadol provides only minimal pain reduction (0.93 points on NRS, below the minimal important difference of 1.0) while increasing serious adverse events including cardiac events 7.

Tramadol Dosing Considerations

If continuing or initiating tramadol 8:

• Start low: 50 mg once or twice daily, titrate every 3 days by 50 mg increments 1, 8
• Maximum dose: 400 mg/day for immediate-release; 300 mg/day for extended-release 9, 8
• Reduce dose for:
  • Age ≥75 years: maximum 300 mg/day 1, 8
  • Renal impairment (CrCl <30 mL/min): 50 mg every 12 hours, maximum 200 mg/day 8
  • Hepatic cirrhosis: 50 mg every 12 hours 8

Critical Safety Considerations

Avoid tramadol or use extreme caution with:

• Concurrent serotonergic medications (SSRIs, SNRIs, TCAs, MAOIs) due to serotonin syndrome risk 1, 9, 10
• CYP2D6 ultrarapid metabolizers (increased toxicity risk) 9
• CYP2D6 poor metabolizers (lack of analgesic effect) 9
• History of seizures (tramadol lowers seizure threshold) 1

Common adverse effects include nausea (NNH 7), dizziness (NNH 8), constipation (NNH 9), and somnolence (NNH 13) 7.

Bottom Line

Do not discontinue tramadol solely because of new tendon pain. Treat the tendon pathology with appropriate evidence-based interventions (topical NSAIDs, rest modification, physical therapy, eccentric exercises). Tramadol continuation should be based on its efficacy for the patient's primary pain condition and overall risk-benefit profile, not on unfounded concerns about tendon toxicity. If tramadol is being considered specifically for tendon pain, recognize that evidence for benefit is limited and other options should be prioritized first 6, 7.